|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
|
|
||
Independent, up-to-date news and information for the multiple myeloma community. |
|
Here are all the latest news articles written by The Beacon's staff.
For articles and press releases about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, Darzalex (daratumumab), Empliciti (elotuzumab), Kyprolis, Ninlaro (ixazomib, MLN9708), Pomalyst (Imnovid), Farydak (panobinostat), Revlimid, thalidomide, Velcade, and Zometa.
For articles and press releases about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), bb2121, BT-062, isatuximab (SAR650984), Keytruda (pembrolizumab), marizomib (NPI-0052), melflufen, MOR202, oprozomib, selinexor (KPT-330), Treanda (bendamustine), Venclexta (venetoclax, ABT-199) and Zolinza (vorinostat).
For articles and press releases about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathy, secondary cancer, smoldering multiple myeloma, and stem cell transplants.
Results of a recent British study indicate that the relative importance of factors affecting survival in multiple myeloma patients changes with patient age.
In particular, the researchers found that the older a patient is at diagnosis, the more their survival is affected by their general health and by how advanced their multiple myeloma is at diagnosis.
In contrast, the impact of high-risk chromosomal abnormalities on survival decreases with patient age.
The study findings are based on an analysis of data for almost 4,000 newly diagnosed multiple myeloma patients who participated …
A team of Dutch researchers has published results of a small study investigating the impact of Darzalex treatment on immunoglobulin levels in multiple myeloma patients.
In their study, the researchers focus in particular on how the levels of a patient’s uninvolved immunoglobulins are affected by treatment with Darzalex.
Uninvolved immunoglobulins in myeloma patients are immunoglobulins that have a type different from any monoclonal immunoglobulin made by a patient’s myeloma cells.
Someone with IgG multiple myeloma, for example, has myeloma plasma cells that produce monoclonal immunoglobulin G (IgG). For this myeloma …
As researchers search for new treatments for multiple myeloma, they are particularly interested in uncovering therapies that address the disease in new ways. Survival and the chance for a cure are likely to be improved the most by new treatments that are noticeably different from other myeloma therapies.
One of the reasons Darzalex (daratumumab), for example, has been such an important new treatment for multiple myeloma is because it represents a new way of treating the disease. Darzalex was not just another immunomodulatory agent, like Revlimid (lenalidomide) or thalidomide, and …
Swiss researchers have published results of a small clinical trial testing whether nelfinavir, a drug originally used to treat AIDS, can overcome resistance to Revlimid in relapsed multiple myeloma patients.
The trial was motivated by previous research showing that nelfinavir can overcome resistance to Velcade, for a period of time, in many relapsed myeloma patients.
Unfortunately, the results of the more recent nelfinavir trial are not as encouraging as the previous research involving nelfinavir and Velcade. Less than a third of the patients in the more recent trial responded to …
A major source of optimism in the myeloma community these days is the large number of potentially very effective treatments under development for the disease.
Increasing the number of effective treatment options for the disease could lead to a sizable jump in survival for both newly diagnosed and relapsed multiple myeloma patients.
There is, however, a common theme among many of the promising investigational therapies for multiple myeloma that could limit their ability to make as large an impact on myeloma survival as many hope. The common theme can be …
There currently are more than 300 clinical trials ongoing around the world that are investigating treatments for multiple myeloma and looking for patient participants. Most of these trials are exploring new myeloma therapies that have not yet been approved for use outside of clinical trials, and many of these “investigational” therapies, as they often are called, have the potential to be extremely effective.
The number of new treatments under development for multiple myeloma is greater than it ever has been, and this creates tremendous hope in the myeloma community. In …
Statistics compiled by The Myeloma Beacon show there is substantial variation across U.S. cancer centers in the number of autologous (own) stem cell transplants the centers perform each year for people with multiple myeloma.
The five busiest U.S. centers in terms of autologous transplants for multiple myeloma carried out an average of 236 such transplants per center in 2017, the latest year for which data are publicly available. That is a pace equal to almost one transplant per weekday at each of the five centers.
In contrast, across the other …
